An Analysis of Cases of Benign Prostatic Hyperplasia in a Tertiary Hospital in Eastern Nigeria: Incidence, Treatment, and Cost of Management
Asian Journal of Research and Reports in Urology,
Background: Benign prostatic hyperplasia (BPH) is one of the most common conditions in aging men. Although BPH is not life threatening, the clinical manifestations such as lower urinary tract symptoms (LUTS) reduce patients’ quality of life. BPH is associated with high healthcare costs and is a burden on the patients’ families and society.
Objective: To assess the incidence, treatment pattern, and direct cost of management of BPH in a tertiary hospital, in Eastern Nigeria.
Methods: A retrospective descriptive assessment of case notes of patients diagnosed with BPH between September 2017 and August 2019. The treatment pattern was assessed for 12 months. Costs were calculated for BPH-related clinical procedures and medications.
Results: The incidence rate of BPH in this population is 6.7%. One-hundred and two case notes were retrieved and evaluated. About 50.4% of the patients visited the hospital between 2 to 4 times, with a mean visit of 4.4 times a year. Ninety-nine percent of the patients received pharmacological interventions, while the combination of alpha blockers and 5-alpha reductase inhibitors was the most frequently prescribed drug therapy for BPH. The total annual direct cost of managing BPH in this healthcare facility is about N4,966,080 (Nigerian Naira), an equivalent of $12,810 USD.
Conclusion: The combination of alpha blockers and 5-alpha reductase inhibitors was the most frequently prescribed drugs for BPH in this facility. Most patients made out-of-pocket payments hence, appropriate treatment options must be selected for each patient in other to prevent complications and reduce costs.
- Benign prostatic hyperplasia
- direct cost
- treatment pattern
How to Cite
American Urological Association Guideline: management of benign prostatic hyperplasia (BPH);2010.
Wang W, Guo Y, Zhang D, Tian Y, Zhang X. The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys. Scientific Reports, 2015;5:13546.
Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative Importance of Sexuality and Quality of Life in Patients with Prostatic Symptoms. Eur Urol, 1997;31:272-280.
Parsons JK , Mougey J , Lambert L ,Wilt TJ , Fink HA , Garzotto M, Barrett‐Connor E, Marshall LM. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int, 2009; 104, 63–68.
Sagnier PP, Girman C, Garraway M, Kumamoto Y, Lieber M, Richard F, MacFariane G, Guess H, Jacobsen J, Tsukamoto T, Boyle P. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol, 1996;29:15–20.
Engstrom G, Walker-Engstrom ML, Loof L, Leppert J. Prevalence of three lower urinary tract symptoms in men-a population-based study. Fam Pract. 2003;20:7–10.
Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol, 2008;40:921–31.
Ezeanyika LUS, Ejike ECC, ObidoaO, & Elom SO. Prostate disorders in an apparently normal Nigerian population 1. Biokemistr. 2006;18(2):127-132.
Ojewola RW, Oridotab ES, Baloguna OS, Alabi TO, Ajayi AI, Olajide TA, Tijani KH, Jeje EA, Ogunjimia MA, Ogundare EO. Prevalence of clinical benign prostatic hyperplasia amongst community-dwelling men in a South-Western Nigerian rural setting. African Journal of Urology. 2017; 23, 109–115.
Bock-Oruma AA, Dienye PO, Oghu IS. Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care, Port Harcourt, Nigeria, South African Family Practice. 2013;5:5.
Kenneth A, Francis A, Christian GK, Ferguson LE, Emmanuel A, Benjamin TF, George A, Emmanuella BN, Portia AA. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia among Ghanaian men: a hospital-based cross-sectional prospective study. Int J Res Med Sci. 2016;4(9):3905-3911.
Almarkhan HM, Sawma AI, Alruwaili FS, Alsaqabi QA, Alonazi MA, Alruwaili WS, Alanazi NH, Alotaibi HJ. Prevalence of Benign Prostatic Hyperplasia (BPH) in Saudi Patients above 40 Years Old. The Egyptian Journal of Hospital Medicine. 2018;70(7):1137-1139.
Sausville J & Naslund M (2010) Benign prostatic hyperplasia and prostate cancer: An overview for primary care physicians. Int J Clin Pract. 2010;64(13):1740–1745.
Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr prostate rep4. 2006;81– 90
Araoye MO. Research Methodology with Statistics for Health and Social Sciences. Nathadex Publisher: Ilorin, Nigeria; 2003.
Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RD, Jiménez Cruz F, Jonas U, MacRae K, Pientka L, Rutten, FF, van Schayck, CP, Speakman, M. J. Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. European urology, 2002;42(4):323–328.
Lee YJ, Lee JW, Park J, Seo SI, Chung JI, Yoo TK & Son H. Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea. Investig Clin Urol. 2016;57(6):424-430.
Black L, Naslund MJ, Gilbert TD, Davis EA & Ollendorf DA. An examination of treatment patterns and cost of care among patients with benign prostatic hyperplasia. American Journal of managed care 2006;12:S99-S110
Jacobsen SJ, Girman C J, Guess, HA, Panser LA, Chute, CG, Oesterling JE, & Lieber MM. Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? Urology, 1995;45(1):64–69.
Sarma AV, Jacobsen SJ, Girman CJ, Jacobson DJ, Roberts RO, Rhodes T & Lieber M. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. The Journal of urology, 2002;168(4 Pt 1): 1446–1452.
Kang JY, Min GE, Son H, Kim HT, Lee HL. National-wide data on the treatment of BPH in Korea. Prostate Cancer Prostatic Dis. 2011;14:243-7.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F. Comb AT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. 2010; Eur Urol.;57(1):123-31.
Shum, CF, Lau W, Teo C Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination. Asian journal of urology. 2017;4(3):185–190.
Odusanya BO, Tijani KH, Jeje EA, Ogunjimi MA, Ojewola RW. Short-term effect of tamsulosin and finasteride monotherapy and their combination on Nigerian men with benign prostatic hyperplasia. Niger J Surg 2017;23:5-10
Nash J. Benign prostatic hyperplasia: prevalence and diagnosis. 2010; GM:40.
Abstract View: 89 times
PDF Download: 44 times